CHMP recommends approval of Novo Nordisk's hemophilia drug for postpartum bleeding
The European Medicines Agency expert committee, the CHMP, has recommended that the indication for Novo Nordisk’s hemophilia drug Novoseven is extended to include women suffering from severe hemorrhaging after giving birth.
by christopher due karlsson, translated by daniel pedersen
On Friday, Novo Nordisk has announced that the European Medicines Agency’s (EMA) expert committee, the CHMP, has adopted a positive opinion of Novoseven as a treatment for severe postpartum hemorrhage, a company press release reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
